Orthofix enters its third-quarter report with an unusual problem: the quarter that matters most for judging its turnaround is also the one with the fewest flattering distractions. Most of the roughly $15 million one-time European distributor order tied to MDR certification is expected to land in the fourth quarter. That leaves the September period as the clearest look yet at whether the company's underlying growth engine is merely idling or actually stalling.
Wall Street expects revenue of about $210.4 million, up a modest 2.3% from $205.6 million a year ago and essentially flat with the $210.9 million posted last quarter. The consensus calls for a loss of $0.31 per share, a meaningful improvement from the $0.57 loss a year earlier and the $0.39 loss last quarter. That 45.6% improvement in the bottom line reflects cost discipline and restored reimbursement more than top-line strength. The revenue forecast lines up almost exactly with the 2% to 3% core back-half growth that management's full-year outlook implies once the European order is stripped out, well below the 5% to 6% pace the company described earlier in the year.
Management's full-year range now sits at $845 million to $855 million, raised from the May outlook largely because Medicare restored bone growth stimulator reimbursement and the European order was added. Yet the Street's full-year revenue estimate of roughly $843 million sits below the bottom of that range. Analysts are effectively saying they do not fully trust the company's math, whether because of the distributor issues in spine or the timing of the European shipment. A third quarter that lands at or above consensus would start to close that credibility gap; a soft one would suggest the range itself is at risk.
The swing factor is US spine fixation, which slowed to 3% growth last quarter from 4% in the first quarter and 6% in 2025. Management flagged that its smaller distributors, about a fifth of spine fixation sales, were shrinking faster than expected and warned that the drag would last through year end, possibly prompting consolidation or exits. Evidence that the top distributors are still growing strongly enough to offset that erosion would validate the strategy. A further slide below 3% would challenge it. On the positive side, investors should look for limb reconstruction to hold near last quarter's 11% constant-currency growth, biologics to stay at least flat after two quarters of improvement, and therapeutic solutions to show the first full-quarter benefit of restored Medicare rates and the AXEL STIM 2.0 launch. Gross margin also deserves attention after slipping to 71.7% versus the 72.5% framing for the year, with international credit losses a lingering concern. Any update on the Virada launch slated for the fourth quarter and on whether the suspended long-range growth plan will return would help restore visibility.
The market has already rendered a harsh verdict on last quarter's cooler tone. Shares have fallen 27.3% since the prior report, against a 2.6% dip for the S&P 500, and at $9.07 they trade well below the 200-day moving average of $11.11 and not far above the post-earnings low of $8.50. Sentiment has swung from mildly bullish heading into the last report to modestly bearish now. That pessimism lowers the bar somewhat, though it also reflects genuine doubts about the quality of this year's guidance raise.
Ultimately, this report comes down to one question: is 2% to 3% core growth a floor or a ceiling? If Orthofix shows spine stabilizing, limb reconstruction and biologics holding their gains, and margins recovering toward plan, the full-year range looks achievable and the selloff looks overdone. If core growth slips further, the European order will look less like a bonus and more like a patch over a weakening business.